A pivotal publication, associated with Empagliflozin, was released on 2023-01-01. The publication, titled "Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, contr (Lancet)", details findings from the RECOVERY trial regarding treatment for COVID-19.
Background
Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, approved for the treatment of type 2 diabetes, heart failure, and chronic kidney disease. The publication itself focuses on the use of higher dose corticosteroids in patients hospitalized with COVID-19 who experience hypoxia but do not require ventilatory support. This research contributes to the understanding of therapeutic strategies for managing severe respiratory complications of COVID-19.
What this means
The publication of these findings from the RECOVERY trial provides important clinical data on the use of corticosteroids for patients hospitalized with COVID-19 who are hypoxic but not yet requiring ventilatory support. While the specific connection between this corticosteroid research and Empagliflozin is not detailed in the provided information, the event is categorized as a pivotal publication related to the drug. This suggests the findings may hold relevance for clinicians and researchers monitoring developments in broader therapeutic areas that could intersect with Empagliflozin's established indications or potential future research directions, or it may indicate a broader interest in therapies for conditions that can be exacerbated by or co-occur with viral infections.
Source
The information regarding this pivotal publication was obtained from PubMed, an online database of biomedical literature. The publication, identified by external ID 37060915, was released on 2023-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.